Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer

Chronic or recurrent inflammation is known to play a causative role in the promotion and progression of many human tumours, including cancers of the liver, oesophagus, stomach, large intestine and urinary bladder [1‐3]. Chronic inflammation has also been implicated in the aetiology of prostate cancer [4‐7]. Prostate cancer risk has been associated with sexually transmitted infections and prostatitis in some epidemiologic studies [8, 9], and its relationship with genetic polymorphisms in inflammatory cytokines has been explored in various case-control studies [10‐13]. Chronic inflammation, alongside the intrinsic properties of pre-malignant cells and other determinants, may therefore be one of the driving forces of malignant transformation. Thus, numerous mediators released in dysregulated chronic inflammation have been found to promote cell growth and invasion, induce mutagenesis and increase angiogenicity [1]. By virtue of these properties, inflammatory mediators favour initiation of malignancy, and if sustained, may also promote progression. In general, many inflammatory conditions are characterized by the recruitment of inflammatory cells, predominantly macrophages, due to the wide variety of bioactive products they release. Cytokines and chemokines produced by activated innate immune cells are the most important components orchestrating the inflammatory-tumour-microenviroment [14]. Most studies have focussed on inflammatory chemokines that promote monocyte migration, primarily MCP-1 and also RANTES (regulated upon activation, normally T cell-expressed and presumably secreted) [15‐17]. Full activation of NF-κB in inflammatory leukocytes resident in preneoplastic sites are likely to exacerbate local M1-inflammation (high TNF-A, high IL-1, high IL-12, low IL-10, low TGF-β) and favour tumourigenesis [18]. In particular, pro-inflammatory cytokines (e.g. IL-1 and TNF), can themselves affect cancer risk [1, 5, 8, 19].

In the present investigation, we studied the role of several polymorphisms reported to have functional and biological relevance in the inflammatory process. The SNPs selected for study have all been found to influence the expression of their respective cytokine in vitro.

TNF is a key mediator of inflammation and may contribute to tumour initiation by stimulating production of genotoxic molecules, which can lead to DNA damage and mutations [20]. Inter-individual variations in TNF-A levels have been attributed to polymorphisms, notably the A allele at -308 (G/A) position in the promotor region of the TNF gene, which has been associated with higher TNF-A transcription levels [21] and an increased risk of several types of cancer [22]. However, findings on TNF-A polymorphisms in prostate cancer have been inconsistent [10‐13]. In fact, evaluation of genetic variation in cytokines and chemokines in relation to inflammation and cancer risk is a complex task. Thus, it is important to investigate the possible role of other genes involved in the inflammation pathway that might influence prostate cancer risk.

Proinflammatory cytokines IL-1A and IL-1B [23, 24] are also produced by monocytes, macrophages and epithelial cells and exhibit similar biological characteristics to TNF-A, including participation in host response to microbial invasion, inflammation and tissue injury [20]. IL-1 polymorphisms have also been linked to gastric [25], hepatocellular [26], lung [27], colorectal [28], vulvar [29] and ovarian [30] cancers. Allele T of the IL1 (-889 C>T) polymorphism has been associated with high production of this cytokine [31].

RANTES chemokine is believed to play a role in antitumour immunity via immune cell recruitment [32]. Polymorphisms in RANTES have been associated with a higher risk of pancreatic cancer, supporting the hypothesis that proinflammatory gene polymorphisms, in combination with proinflammatory conditions, may influence the development of pancreatic cancer [33].

Finally, MCP-1, a member of the CC chemokine family, possesses chemotactic activity for monocytes and T lymphocytes [34, 35] and has been proposed to play a key role in macrophage recruitment, expression of angiogenic factors and activation of matrix metalloproteinases in breast cancer patients. Genetic variants within regulatory regions of MCP-1 that affect transcription and protein production have been correlated with the risk of breast cancer metastasis [36]. This finding is consistent with the previously reported overexpression of MCP-1 in breast cancer tissue [37].

These cytokines and chemokines were selected for our study because they are released in response to various forms of cellular stress, including inflammation and carcinogen exposure. The objective of this study was to assess the influence of genetic polymorphism of RANTES, MCP-1, IL-1A and TNF-A on the risk of prostate cancer.

The study included 296 patients recently diagnosed with prostate cancer and 311 blood donors (controls). Table 2 shows the genotype and allelic distributions of the polymorphisms in cases and controls, with estimated ORs. None of the SNP genotype frequencies deviated from Hardy-Weinberg equilibrium, and the distributions of alleles in the control group were in agreement with findings in other Spanish Caucasian populations [41]. Polymorphisms could sometimes not be genotyped because of PCR amplification problems, explaining discrepancies in the numbers of cases among groups. Associations were obtained by comparing with the control population (not age-matched). Comparison of TNF-A promoter polymorphisms between patients and controls revealed statistically significant differences in genotype distribution for locus -308, with a higher frequency of A carriers (AA/AG) in patients than in controls (OR = 1.61; 95% CI: 1.09–2.64 p = 0.017). Patients also showed a higher frequency of A allele in the RANTES -403 G/A polymorphism versus controls (OR = 1.44; 95% CI: 1.09–2.38 p = 0.039). In contrast, MCP-1 2518 G/A and IL-1 A- 889 T allele genotypes showed no significant differences between prostate cancer and control groups (Table 2), suggesting that these two genotypes may not play a role in susceptibility to prostate cancer.

We stratified the data, grouping subjects according to their carrier status for IL1-A allele T, TNF-A allele A, RANTES allele A and MCP-1 allele G. In logistic regression analyses, no significant association with prostate cancer risk was found for IL1 or MCP-1 allele carrier status, but subjects with AG or AA genotypes for TNF-A or RANTES had increased prostate cancer risk versus those with GG genotype (Table 2). The combination of the A allele of TNF and RANTES markedly increased this risk (OR, 2.45; 95% CI, 1.22 – 4.94, p = 0.012), although no epistatic effect (p = 0.416) was observed between these polymorphisms. SNP genotypes were also compared within the patient group and stratified according to tumour stage and serum PSA level (Table 1) to determine whether the genotypes influenced these indicators. No significant associations were observed.

Several polymorphisms have been associated with the severity of or susceptibility to numerous inflammatory diseases. In this case-control study, we investigated the association between polymorphisms in cytokine/chemokine genes (TNF-A -308 G/A, RANTES-403 G/A, IL-1A -889 C/T and MCP-1 2518 G/A) and prostate cancer risk. Reports on TNF-A gene polymorphisms and prostate cancer have been controversial [10‐13]. Our results suggest that the A allele, associated with a high production of TNF-A, is linked to an increased risk for prostate cancer. TNF-A, a major factor in the inflammation response, has been related to many types of cancer, e.g., T-cell large granular lymphocyte leukaemia [42], cholestatic liver cancer, multiple myeloma, bladder cancer, hepatocellular carcinoma, gastric cancer and breast cancer [22]. However, no association has been described with nasopharyngeal carcinoma [43] or cervix carcinoma [44]. Discrepancies in some previously published results for TNF-A gene polymorphisms in prostate cancer may be related to the modest risk found. Inflammation is a highly complex process that involves hundreds of genes. The fact that numerous gene polymorphisms contribute to the inflammatory response adds further complexity to the analysis of a specific polymorphism, because each individual gene is likely to contribute only modestly to the risk. Thus, TNF-A may interact in important ways with multiple cytokine/chemokines involved in inflammation pathways that also display genetic variation.

The discrepant results may be explained by the effects of genetic heterogeneity and different gene-environment interactions. Although the distribution of -308A TNF-A has been found to vary among control groups due to ethnic variations [44], the distribution of the allelic frequencies in our study was similar to a recent report [13]. The influence of other (non-inflammation-related) genes or environmental factors is more likely to account for differences. Thus, there is evidence that prostate cancer has a complex and multifactorial aetiology, which might explain discrepancies in the attribution of prostate cancer risk to a single SNP [45]. Furthermore, discrepant results between the NorthAmerican [13] and the present study might be influenced by differences in diet, lifestyle and NSAID use between the study populations.

In this context, differences in NF-kB polymorphism were reported between Spanish and North American groups in association with ulcerative colitis [46]. Finally, a Sweden Study [47, 48] found that increased risk for this type of tumour is probably also influenced by other genes that regulate inflammation (Toll-like receptor) and modify individual susceptibility to prostate cancer. The combined effect of several polymorphism loci is likely to markedly increase the risk of prostate cancer.

Gene-cluster polymorphisms in the interleukin-1 (IL1B) are associated with an increased risk of gastric and other types of cancer [25, 30, 49]. However, no associations have been found between polymorphisms in the IL1 gene cluster (IL1A, IL1B and IL1R) and ovarian or breast cancer [50, 51]. Other authors reported no overall association between IL-1 polymorphisms and gastric cancer [52], and the reason for these different findings are unclear. The present case-control study in Caucasian men found no significant effect of IL1A (-889 C>T) gene polymorphisms on prostate cancer risk.

Chemokines are also expressed in inflammation, attracting and recruiting populations of immune effector cells to injury or infection sites, and the relationship between prostate cancer risk and polymorphisms of RANTES and MCP-1 was investigated in this study. No link with the MCP-1 polymorphism was observed, but a significant association was found between the A allele of RANTES and prostate cancer risk (p = 0.039). Allele A in RANTES is associated with increased transcription, which is related to inflammation and antitumour immunity via immune cell recruitment [53]. The allele A of RANTES and TNF-A has been associated with pancreatitis, especially as a possible early sign of pancreatic cancer [33]. In our study, the same alleles (TNF-A and RANTES) were also associated with a higher prostate cancer risk. Interestingly, the simultaneous presence of allele A of both genes promotes a higher risk (OR = 2.45, p = 0.012) of cancer, but the interaction analysis showed no epistatic interaction between them (p = 0.416), indicating that their effects were additive. Finally, our study has some evident limitations and false positive results cannot be ruled out: thus, size of the study population is relatively small, aged-matched controls were not used and a possible bias corresponding to age cannot be excluded. However, even if we would have used a totally age-matched control subjects, our results would have been with even higher significance, because in this control group we cannot rule out a possibility that some of the younger control subjects may develop prostate cancer later in their life. In addition, there was no difference found between our control subjects and those used from our geographic area in a study of age-related diseases [54, 55]. In general, we would like to comment that the influence of age on the immune gene polymorphism remains controversial. Some publications indicate that there are no differences in genotype distribution between older and younger controls [56], whereas others have reported an age-dependent difference in polymorphism of certain genes [57].

There is a need for studies of larger patient groups, including other potential functional polymorphisms in linkage disequilibrium to determine the role of these polymorphisms in prostate cancer.

In conclusion, our data suggest an important role for TNF-A and RANTES polymorphisms in prostate cancer, as observed in many other types of cancer. Other genetic polymorphisms involved in innate immunity and chronic inflammation have been associated with prostate cancer [48], and the present findings support the hypothesis that the inflammatory process may constitute an important step in the initiation and promotion of prostate cancer.